Recombinant human interferon α2a for injection

Pharmacology: Recombinant human interferon alpha; 2a has broad-spectrum antiviral, anti-tumor and immunomodulatory functions. Interferon binds to cell surface receptors, induces cells to produce a variety of antiviral proteins, inhibits virus reproduction in cells, and improves immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. Toxicology: Acute toxicity test: The maximum dose was injected intravenously or intramuscularly into mice, all of them survived, no death, and the LD50 was not measured. Long-term toxicity test: Rats were given the drug continuously for one month, and all animals survived without abnormal reactions.

Main ingredients: Recombinant human interferon α2a

This product is a white or slightly yellow loose body with no signs of melting; after redissolution, it becomes a clear liquid without any insoluble matter visible to the naked eye.

1. Viral diseases: adult patients with chronic active hepatitis B accompanied by viral replication markers such as HBV-DNA, DNA polymerase positive or HBeAg positive, adult patients with acute and chronic hepatitis C accompanied by positive HCV antibodies and elevated alanine aminotransferase (ALT) but without liver function decompensation (Child classification A), genital warts, herpes zoster, pediatric viral pneumonia and upper respiratory tract infection, chronic cervicitis, hepatitis D, etc. 2. Tumors: hairy cell leukemia, multiple myeloma, non-Hodgkin's lymphoma, chronic leukemia, Kaposi's sarcoma, renal cancer, laryngeal papilloma, melanoma, mycosis fungoides, bladder cancer, basal cell carcinoma, etc.

1. Starting dose for hairy cell leukemia: 3 million international units per day, subcutaneously or intramuscularly, for 16 to 24 weeks. If tolerance is poor, the daily dose should be reduced to 1.5 million international units, or the frequency of administration should be changed to 3 times a week, or both the dose and frequency of administration can be reduced. Maintenance dose: 3 million international units each time, subcutaneously or intramuscularly 3 times a week. If tolerance is poor, the daily dose should be reduced to 1.5 million international units 3 times a week. Course of treatment: After using the drug for about 6 months, the doctor will decide whether to continue the drug for patients with good efficacy or to stop the drug for patients with poor efficacy. Note: For patients with thrombocytopenia (platelet count less than 50109/L) or with

A small number of patients may experience fever, chills, fatigue, myalgia, anorexia, etc. after using this product. Most adverse reactions disappear 48 hours after injection. Other possible adverse reactions include headache, joint pain, loss of appetite, nausea, etc. Some patients may experience granulocytopenia, thrombocytopenia, etc., which can be restored after stopping the drug. If intolerable severe adverse reactions occur, the dose should be reduced or the drug should be stopped, and necessary symptomatic treatment should be given.

1. Patients with a history of allergy to recombinant human interferon alpha;2a or any component of the preparation. 2. Patients with severe heart disease or a history of heart disease. 3. Patients with severe liver, kidney or bone marrow dysfunction. 4. Patients with epilepsy and central nervous system damage. 5. Patients with hepatitis accompanied by advanced decompensated liver disease or cirrhosis. 6. Patients with chronic hepatitis who are currently receiving or will receive immunosuppressive therapy in the near future, except for those who are undergoing short-term hormone-free therapy. 7. Patients with HLA antibody-related chronic myeloid leukemia who are about to receive allogeneic bone marrow transplantation.

Precautions during pregnancy and lactation: Although animal experiments have not shown that recombinant human interferon alpha; 2a has teratogenic effects, its harm to human embryos cannot be ruled out. When recombinant human interferon alpha; 2a was used in early to mid-pregnancy rhesus monkeys at doses far exceeding clinical doses, recombinant human interferon alpha; 2a was observed to have an abortion effect. It is not clear whether recombinant human interferon alpha; 2a can be secreted in human milk, so whether to terminate breastfeeding or medication should be decided based on the importance of the mother. Precautions for the elderly: Elderly patients with heart disease and elderly patients with advanced cancer should undergo electrocardiograms before and during treatment with this preparation, and adjust the dose or stop the medication as needed according to the doctor's advice.

Recombinant human interferon alpha;2a may affect the oxidative metabolism process by reducing the activity of intrahepatic microsomal cytochrome P450. Reports have confirmed that the clearance of theophylline in the body decreases after starting to use recombinant human interferon alpha;2a. Neurotoxicity, hematotoxicity, and cardiac toxicity caused by drugs taken previously or recently will increase due to the use of recombinant human interferon alpha;2a. Interactions will occur when used in combination with drugs with central effects.

Store at 2-8℃ away from light. Valid for 24 months.

6 million IU

2 years and 6 months

Beijing Shougang Gas Company Limited

• Founded in:

  1997-11-14

• Address:

  No. 200, Renli Road, Liqiao Town, Shunyi District, Beijing

• Tax NO.:

  91110107102284454Q

• Registered Funds:

  75.462 million yuan

• Website:

  Log in to view

• Email:

  Log in to view